<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02218034</url>
  </required_header>
  <id_info>
    <org_study_id>190168-069</org_study_id>
    <nct_id>NCT02218034</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety, tolerability and pharmacokinetics study of AGN-190168 in subjects with acne
      vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Level (Cmax) of AGN-190168</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Level (Cmax) of AGN-190168 Metabolite</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Dermal Tolerability as Assessed by the Subject Using a 4-Point Scale</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Dermal Tolerability as Assessed by the Investigator Using a 4-Point Scale</measure>
    <time_frame>Day 29</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>AGN-190168 Formulation 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-190168 Formulation 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAZORAC® Gel 0.1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAZORAC® Gel 0.1% (tazarotene gel 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAZORAC® Cream 0.1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAZORAC® Cream 0.1% (tazarotene cream 0.1%) applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-190168 Formulation 1</intervention_name>
    <description>AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.</description>
    <arm_group_label>AGN-190168 Formulation 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-190168 Formulation 2</intervention_name>
    <description>AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.</description>
    <arm_group_label>AGN-190168 Formulation 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tazarotene gel 0.1%</intervention_name>
    <description>Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.</description>
    <arm_group_label>TAZORAC® Gel 0.1%</arm_group_label>
    <other_name>TAZORAC® Gel 0.1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tazarotene cream 0.1%</intervention_name>
    <description>Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.</description>
    <arm_group_label>TAZORAC® Cream 0.1%</arm_group_label>
    <other_name>TAZORAC® Cream 0.1%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of acne vulgaris on the face

          -  No tobacco use for the past 30 days, and willing to refrain from nicotine use during
             the study

          -  Willing to avoid excessive or prolonged exposure of the treated skin to ultraviolet
             light (eg, sunlight, tanning beds) and extremes in weather, such as wind or cold,
             throughout the study

          -  If male, willing to maintain routine shaving regimen for the duration of the study and
             avoid shaving 12 hours prior to specified visits

          -  Females of childbearing potential must use a reliable method of contraception

        Exclusion Criteria:

          -  Use of phototherapy devices (eg, ClearLight™) and adhesive cleansing strips (eg,
             Ponds® and Biore®), as well as cosmetic procedures (eg, facials, peeling, and comedone
             extraction) in the area to be treated in the past 1 week

          -  Use of topical anti-inflammatory drugs, salicylic acid (eg, Clearasil® and Clean &amp;
             Clear®), corticosteroids, antibiotics, antibacterials (including benzoyl
             peroxide-containing products [eg, benzamycin]), retinoids, and other topical acne
             treatments (eg, photodynamic therapy, laser therapy, and medicated soaps) in the area
             to be treated in the past 2 weeks

          -  Ability to abstain from caffeine-containing products on the dates instructed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2014</study_first_submitted>
  <study_first_submitted_qc>August 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2014</study_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazarotene</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

